What is Biogen's cash & equivalents?

Biogen (BIIB) reported cash & equivalents of $3.38B in Q1 2026.

How has Biogen's cash & equivalents changed year-over-year?

Biogen's cash & equivalents increased by 30.2% year-over-year, from $2.6B to $3.38B.

What is the long-term trend for Biogen's cash & equivalents?

Over 5 years (2020 to 2025), Biogen's cash & equivalents has grown at a 17.7% compound annual growth rate (CAGR), from $1.33B to $3.01B.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Biogen BIIB Cash & Equivalents

Cash & Equivalents at other companies

Eli LillyLLY

$5.28B+70.8%

Rogers CorporationROG

$195.8M+11.5%

TG TherapeuticsTGTX

$442.21M+235%

Acadia PharmaceuticalsACAD

$282.21M+29.6%

AnaptysBio, Inc.ANAB

$248.47M+152%

Syndax PharmaceuticalsSNDX

$130.89M-15.0%

Other financials

Income statement

See full

Revenue$2.5B+1.9%

Gross profit$1.8B+0.8%

Operating income$610.7M—

Net income$319.5M+32.8%

EPS (diluted)$2.15+31.1%

Balance sheet

See full

Total debt$6.6B+34.7%

Total equity$18.7B+9.9%

Total assets$29.5B+5.2%

Cash flow

See full

Operating cash flow$645.5M+149%

CapEx$51.2M+38.0%

Free cash flow$594.3M+167%

Valuation

See full

Market cap$31.9B+71.6%

Enterprise value$35.08B+56.4%

P/E22.5×+10.3×

P/S3.2×+1.4×

Profitability

See full

Gross margin75.5%-0.1pp

Operating margin22.9%—

Net margin14.3%-0.8pp

FCF margin24.4%-0.4pp

Returns & leverage

See full

Return on equity8%-1.2pp

Debt / equity0.4×+0.1×

Current ratio3.1×+1.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biogen's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Biogen's cash & equivalents?: Biogen (BIIB) reported cash & equivalents of $3.38B in Q1 2026.
How has Biogen's cash & equivalents changed year-over-year?: Biogen's cash & equivalents increased by 30.2% year-over-year, from $2.6B to $3.38B.
What is the long-term trend for Biogen's cash & equivalents?: Over 5 years (2020 to 2025), Biogen's cash & equivalents has grown at a 17.7% compound annual growth rate (CAGR), from $1.33B to $3.01B.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.